Table 1.
Sample characteristics according to tertile of the log-transformed plasma level of BNP at the time of bioimpedance analysis
| Sample characteristics | Log-transformed plasma level of BNP |
p for trend | ||
|---|---|---|---|---|
| tertile 1 (<3.03) | tertile 2 (3.03–4.16) | tertile 3 (≥4.17) | ||
| (n = 49) | (n = 49) | (n = 49) | ||
| Age, years | 61.5±13.8 | 67.3±10.8 | 72.2 ±12.2 | <0.001 |
| Male sex, n (%) | 35 (71.4) | 32 (65.3) | 31 (63.3) | 0.67 |
| Diabetes mellitus, n (%) | 14 (28.6) | 14 (28.6) | 13 (26.5) | 0.97 |
| Presence of cardiac comorbidities, n (%) | 5 (10.2) | 15 (30.6) | 27 (55.1) | <0.001 |
| BMI | 27.5±4.2 | 25.0±3.2 | 23.3 ±3.7 | <0.001 |
| Systolic blood pressure, mm Hg | 130±18 | 132±19 | 130 ±21 | 0.90 |
| Diastolic blood pressure, mm Hg | 77±13 | 73±13 | 69 ±12 | 0.002 |
| Pulse pressure, mm Hg | 53±13 | 58±16 | 60 ±19 | 0.031 |
| Resistant high blood pressure, n (%) | 16 (32.7) | 17 (34.7) | 25 (51.0) | 0.14 |
| Serum sodium, mEq/l | 140.3±2.6 | 139.8±3.0 | 138.1 ±4.2 | 0.002 |
| Serum potassium, mEq/l | 4.5±0.5 | 4.6±0.6 | 4.4 ±0.7 | 0.30 |
| Serum creatinine, mg/dl | 2.05±1.38 | 3.30±3.36 | 5.36 ±3.88 | <0.001 |
| eGFRMDRD, ml/min per 1.73 m2 | 37±23 | 29±19 | 15 ±10 | <0.001 |
| GFR categories in KDIGO 2012 | ||||
| G1 or 2, n (%) | 7 (14.3) | 3 (6.1) | 0 (0.0) | <0.001 |
| G3a or G3b, n (%) | 17 (34.7) | 19 (38.8) | 4 (8.2) | |
| G4, n (%) | 16 (32.7) | 12 (24.5) | 12 (24.5) | |
| G5, n (%) | 9 (18.4) | 15 (30.6) | 33 (67.3) | |
| Serum albumin, mg/dl | 4.0±0.5 | 3.9±0.5 | 3.5 ±0.5 | <0.001 |
| Total cholesterol, mg/dl | 186±45 | 177±43 | 168 ±38 | 0.048 |
| Triglyceride, mg/dl | 180±108 | 167±98 | 126 ±73 | <0.001 |
| Fasting blood glucose, mg/dl | 120±36 | 121±44 | 132 ±48 | 0.14 |
| C-reactive protein, mg/dl | 0.2±0.2 | 0.2±0.5 | 0.5 ±1.0 | 0.030 |
| UPCR, g/g·Cr | 1.6±3.0 | 2.0±3.4 | 2.8 ±2.7 | 0.010 |
| Brain natriuretic peptide, pg/ml | 10.9±5.4 | 36.3±12.5 | 393 ±542 | <0.001 |
| Geriatric nutritional risk index | 111±11 | 106±9 | 96 ±12 | <0.001 |
| Total body water, l | 34.9±8.3 | 33.2±6.7 | 31.5 ±7.7 | 0.005 |
| % in body weight | 48.5±6.6 | 50.6±5.9 | 53.0 ±7.2 | <0.001 |
| ICWBIA, l | 21.2±5.2 | 19.9±4.0 | 18.7 ±4.7 | <0.001 |
| % in body weight | 29.0±4.3 | 30.4±3.6 | 31.4 ±4.3 | <0.001 |
| ECWBIA, l | 13.8±3.2 | 13.2±2.7 | 12.8 ±3.0 | 0.045 |
| % in body weight | 19.1±2.4 | 20.2±2.5 | 21.6 ±3.0 | <0.001 |
| Water-free contents, kg | 37.4±10.4 | 32.5±7.2 | 28.0 ±7.3 | <0.001 |
| % in body weight | 51.5±6.6 | 49.4±5.9 | 47.0 ±7.2 | <0.001 |
| Ratio of ECWBIA/ICWBIA | 0.65±0.03 | 0.66±0.02 | 0.69 ±0.03 | <0.001 |
| Furosemide, n (%) | 8 (16.3) | 10 (20.4) | 27 (55.1) | <0.001 |
| Other diuretics, n (%) | 8 (16.3) | 10 (20.4) | 9 (18.4) | 0.89 |
| ACE inhibitors, n (%) | 10 (20.4) | 10 (20.4) | 4 (8.2) | 0.55 |
| AT1 receptor blockers, n (%) | 41 (83.7) | 34 (69.4) | 23 (46.9) | <0.001 |
| Other antihypertensives | 31 (63.3) | 32 (65.3) | 46 (93.9) | <0.01 |
eGFRMDRD = Estimated glomerular filtration rate by the Modification of Diet in Renal Disease method; KDIGO = Kidney disease: improving global outcomes; BIA = bioelectrical impedance analysis; ACE inhibitors = angiotensinconverting enzyme inhibitors; AT1 receptor blockers = angiotensin II type 1 receptor blockers.